Loading…
Loading…
EQUITY / NASDAQ · XNCM
Capricor Therapeutics, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗9.25 USD · -2.3231%
Observed: Oct 1, 2026, 9:41 AM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 9.47 USD · Volume 20,441,412
251 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Cash and cash equivalents | 20,935,187 USD | — | — |
| Net income | -40,733,654 USD | -25,910,791 USD | — |
| Operating profit | -42,945,620 USD | -27,717,534 USD | — |
| Total assets | 368,735,835 USD | — | — |
| Total equity | 246,218,890 USD | 104,977,056 USD | +134.55% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 20,935,187 USD | — | — | 287,847,312 USD | 287,847,312 USD | 19,510,383 USD | — | — |
| Net incomeIncome statement | -40,733,654 USD | -74,674,999 USD | -33,941,345 USD | — | -105,043,946 USD | -24,570,647 USD | -74,873,032 USD | -25,910,791 USD |
| Operating profitIncome statement | -42,945,620 USD | -79,718,473 USD | — | — | -108,142,130 USD | -26,284,040 USD | -78,986,122 USD | -27,717,534 USD |
| Total assetsBalance sheet | 368,735,835 USD | — | — | 355,949,294 USD | 355,949,294 USD | 126,438,207 USD | — | — |
| Total equityBalance sheet | 246,218,890 USD | — | 278,702,633 USD | 305,792,145 USD | 305,792,145 USD | 83,867,255 USD | — | 104,977,056 USD |
| Total liabilitiesBalance sheet | 122,516,945 USD | — | — | 50,157,149 USD | 50,157,149 USD | 42,570,952 USD | — | — |
| Capital expendituresCash flow statement | — | 9,184,644 USD | — | — | 2,904,461 USD | — | 1,239,588 USD | — |
| Financing cash flowCash flow statement | — | -2,772,403 USD | — | — | 248,892,296 USD | — | 76,884 USD | — |
| Investing cash flowCash flow statement | — | -203,399,644 USD | — | — | 97,479,281 USD | — | 54,391,021 USD | — |
| Operating cash flowCash flow statement | — | -60,740,078 USD | — | — | -69,811,261 USD | — | -46,244,518 USD | — |
| RevenueIncome statement | — | — | — | — | 0 USD | — | — | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/17/2026 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.